Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.
Saved in:
| Title: | Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib. |
|---|---|
| Authors: | Bowman C; Genentech, Inc., South San Francisco, California, USA., Dolton M; Genentech, Inc., South San Francisco, California, USA., Ma F; Genentech, Inc., South San Francisco, California, USA., Cheeti S; Genentech, Inc., South San Francisco, California, USA., Kuruvilla D; Genentech, Inc., South San Francisco, California, USA., Sane R; Genentech, Inc., South San Francisco, California, USA., Kassir N; Genentech, Inc., South San Francisco, California, USA., Chen Y; Genentech, Inc., South San Francisco, California, USA. |
| Source: | CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Apr; Vol. 13 (4), pp. 660-672. Date of Electronic Publication: 2024 Mar 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2163-8306 |
|---|---|
| DOI: | 10.1002/psp4.13114 |
